NO133713B - - Google Patents
Download PDFInfo
- Publication number
- NO133713B NO133713B NO219371A NO219371A NO133713B NO 133713 B NO133713 B NO 133713B NO 219371 A NO219371 A NO 219371A NO 219371 A NO219371 A NO 219371A NO 133713 B NO133713 B NO 133713B
- Authority
- NO
- Norway
- Prior art keywords
- lower alkyl
- nitro
- sodium
- methyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- LUAJUWOJEFFNFE-UHFFFAOYSA-N 2-chloro-5-methyl-3-nitropyridine Chemical compound CC1=CN=C(Cl)C([N+]([O-])=O)=C1 LUAJUWOJEFFNFE-UHFFFAOYSA-N 0.000 claims 1
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 claims 1
- QCQICELALGZQRL-UHFFFAOYSA-N 2-methoxy-5-methyl-3-nitropyridine Chemical compound COC1=NC=C(C)C=C1[N+]([O-])=O QCQICELALGZQRL-UHFFFAOYSA-N 0.000 claims 1
- QAINEQVHSHARMD-UHFFFAOYSA-N 5-methyl-3-nitro-1h-pyridin-2-one Chemical compound CC1=CNC(=O)C([N+]([O-])=O)=C1 QAINEQVHSHARMD-UHFFFAOYSA-N 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 239000003208 petroleum Substances 0.000 claims 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 9
- 210000002683 foot Anatomy 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- -1 amino-substituted pyridones Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000002084 enol ethers Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- BOAFCICMVMFLIT-UHFFFAOYSA-N 3-nitro-1h-pyridin-2-one Chemical compound OC1=NC=CC=C1[N+]([O-])=O BOAFCICMVMFLIT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000005748 halopyridines Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
Landscapes
- Pyridine Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO219371A NO133713C (index.php) | 1969-11-12 | 1971-06-10 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87605869A | 1969-11-12 | 1969-11-12 | |
| US4554770A | 1970-06-11 | 1970-06-11 | |
| NO429470A NO134907C (index.php) | 1969-11-12 | 1970-11-11 | |
| NO219371A NO133713C (index.php) | 1969-11-12 | 1971-06-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO133713B true NO133713B (index.php) | 1976-03-08 |
| NO133713C NO133713C (index.php) | 1976-06-16 |
Family
ID=27483995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO219371A NO133713C (index.php) | 1969-11-12 | 1971-06-10 |
Country Status (1)
| Country | Link |
|---|---|
| NO (1) | NO133713C (index.php) |
-
1971
- 1971-06-10 NO NO219371A patent/NO133713C/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO133713C (index.php) | 1976-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI66000C (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 2-amino-4-pyrimidonderivat | |
| NO176759B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater | |
| WO1996039133A1 (en) | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones | |
| US7790759B2 (en) | Glycyrrhetinic acid-30-amide derivatives and their use | |
| DE3035086C2 (index.php) | ||
| KR860000931B1 (ko) | 궤양 치료제인 2-구아니디노-4-(2-치환된-아미노-4-이미다졸릴)-티아졸의 제조방법 | |
| IL35098A (en) | Pharmaceutical compositions containing mono-amides of phthalic and pyridine dicarboxylic acids | |
| JPS58159489A (ja) | ２，３−ジアリ−ル−５−ハロチオフエン化合物 | |
| NO156086B (no) | Analogifremgangsmaate for fremstilling av substituerte heterocykliske fenoksyaminer. | |
| US4636513A (en) | Isoxazole derivatives and medicaments containing these compounds | |
| EP0005559B1 (de) | Phenylaminothiophenessigsäuren, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| NO133713B (index.php) | ||
| JPH0227969B2 (index.php) | ||
| JPS5914037B2 (ja) | イソキノリン誘導体、その製造方法およびそれを含有する医薬組成物 | |
| JPH03504497A (ja) | 新規フルオルアルコキシ化合物 | |
| US4477463A (en) | Antiinflammatory and/or analgesic 1-alkyl-4,5-diaryl-2-fluoroalkyl-1H-pyrroles | |
| DE3204153A1 (de) | Substituierte thienobenzodiazepinone, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| JPS6248657A (ja) | 抗炎症活性および鎮痛活性を有する化合物および組成物 | |
| Sabina et al. | Analgesic, antipyretic and ulcerogenic effects of Indian Ayurvedic Herbal formulation Triphala | |
| JPS635025B2 (index.php) | ||
| KR910002582B1 (ko) | 항궤양성 피리미딘 유도체 | |
| JPH01149792A (ja) | ６‐クロロ‐４‐ヒドロキシ‐２‐メチル‐Ｎ‐（２‐ピリジル）‐２Ｈ‐チエノ〔２，３‐ｅ〕‐１，２‐チアジン‐３‐カルボキサミド‐１，１‐ジオキシドのエノールエーテル、その製造方法および用途 | |
| JPH02124889A (ja) | イミダゾピラゾール誘導体 | |
| HUT62004A (en) | Process for producing new piperazinoalkyl benzoxazine and thiazine derivatives with heterocyclic substituent, as well as pharmaceutical compositions comprising such compounds | |
| JPS63230670A (ja) | 置換ピリジル酢酸誘導体 |